11/21
09:10 am
dyn
Paragon Therapeutics Appoints Susanna High as Chief Executive Officer [Yahoo! Finance]
Low
Report
Paragon Therapeutics Appoints Susanna High as Chief Executive Officer [Yahoo! Finance]
11/13
06:51 pm
dyn
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $50.00 price target on the stock.
High
Report
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $50.00 price target on the stock.
11/13
10:08 am
dyn
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $55.00 price target on the stock.
High
Report
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $55.00 price target on the stock.
11/12
07:30 am
dyn
Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Medium
Report
Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
11/7
04:15 pm
dyn
Dyne Therapeutics to Present at Upcoming Investor Conferences
Low
Report
Dyne Therapeutics to Present at Upcoming Investor Conferences
11/4
06:15 pm
dyn
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
Low
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
11/4
11:00 am
dyn
The Schall Law Firm Encourages Investor Participation In An Inquiry Into Dyne Therapeutics, Inc. For Possible Securities Law Violations
Low
Report
The Schall Law Firm Encourages Investor Participation In An Inquiry Into Dyne Therapeutics, Inc. For Possible Securities Law Violations
11/3
11:00 am
dyn
Dyne Therapeutics Inc Is Being Investigated For Securities Fraud And Affected Shareholders Are Urged To Contact The Schall Law Firm
Low
Report
Dyne Therapeutics Inc Is Being Investigated For Securities Fraud And Affected Shareholders Are Urged To Contact The Schall Law Firm
11/2
11:00 am
dyn
The Schall Law Firm Encourages Investor Participation In A Case Against Dyne Therapeutics, Inc. For Securities Law Violations
Low
Report
The Schall Law Firm Encourages Investor Participation In A Case Against Dyne Therapeutics, Inc. For Securities Law Violations
11/2
11:00 am
dyn
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
Low
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
10/31
10:30 pm
dyn
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
Low
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
10/31
11:00 am
dyn
Dyne Therapeutics Inc Is Being Sued For Securities Fraud And Shareholders With Losses Are Urged To Contact The Schall Law Firm
Low
Report
Dyne Therapeutics Inc Is Being Sued For Securities Fraud And Shareholders With Losses Are Urged To Contact The Schall Law Firm
10/30
11:00 am
dyn
The Schall Law Firm Encourages Investors To Join A Case Against Dyne Therapeutics, Inc. For Securities Law Violations
Low
Report
The Schall Law Firm Encourages Investors To Join A Case Against Dyne Therapeutics, Inc. For Securities Law Violations
10/29
12:00 pm
dyn
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
Neutral
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
10/29
11:00 am
dyn
Dyne Therapeutics Inc May Have Committed Securities Fraud And Stockholders With Losses Are Urged To Reach Out To The Schall Law Firm
Low
Report
Dyne Therapeutics Inc May Have Committed Securities Fraud And Stockholders With Losses Are Urged To Reach Out To The Schall Law Firm
10/28
11:00 am
dyn
Dyne Therapeutics Inc Is Being Investigated For Securities Fraud And Affected Shareholders Are Urged To Contact The Schall Law Firm
Low
Report
Dyne Therapeutics Inc Is Being Investigated For Securities Fraud And Affected Shareholders Are Urged To Contact The Schall Law Firm
10/27
12:00 pm
dyn
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
Low
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
10/27
11:00 am
dyn
The Schall Law Firm Encourages Investors To Join An Inquiry Into Dyne Therapeutics, Inc. For Securities Law Violations
Low
Report
The Schall Law Firm Encourages Investors To Join An Inquiry Into Dyne Therapeutics, Inc. For Securities Law Violations
10/26
11:00 am
dyn
Dyne Therapeutics Inc Is Being Investigated For Securities Fraud And Shareholders With Losses Are Urged To Contact The Schall Law Firm
Low
Report
Dyne Therapeutics Inc Is Being Investigated For Securities Fraud And Shareholders With Losses Are Urged To Contact The Schall Law Firm
10/25
05:52 pm
dyn
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
Low
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
10/25
11:00 am
dyn
The Schall Law Firm Encourages Investors To Join An Inquiry Into Dyne Therapeutics, Inc. For Securities Law Violations
Low
Report
The Schall Law Firm Encourages Investors To Join An Inquiry Into Dyne Therapeutics, Inc. For Securities Law Violations
10/24
11:00 am
dyn
Dyne Therapeutics Inc Is Being Investigated For Securities Fraud And Affected Shareholders Are Urged To Contact The Schall Law Firm
Low
Report
Dyne Therapeutics Inc Is Being Investigated For Securities Fraud And Affected Shareholders Are Urged To Contact The Schall Law Firm
10/24
07:15 am
dyn
Dyne Therapeutics, Inc. (NASDAQ: DYN) was downgraded by analysts at JPMorgan Chase & Co. from an "overweight" rating to a "neutral" rating. They now have a $35.00 price target on the stock, down previously from $43.00.
Low
Report
Dyne Therapeutics, Inc. (NASDAQ: DYN) was downgraded by analysts at JPMorgan Chase & Co. from an "overweight" rating to a "neutral" rating. They now have a $35.00 price target on the stock, down previously from $43.00.
10/23
06:30 pm
dyn
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
Low
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
10/23
11:00 am
dyn
The Schall Law Firm Encourages Investors To Join An Inquiry Into Dyne Therapeutics, Inc. For Securities Law Violations
Low
Report
The Schall Law Firm Encourages Investors To Join An Inquiry Into Dyne Therapeutics, Inc. For Securities Law Violations